I-ABK Biomedical, Inc. ibhengeze isigulana sokuqala esinyangwe kuphononongo lokuQala kuBantu lwe-ABK kunye ne-Eye90 microspheres™, isixhobo se-Y90 se-radioembolization kunyango lwe-cancer yesibindi. Olu phononongo lwenziwa ngentsebenziswano neYunithi yoPhando lweSibhedlele sase-Auckland, eNew Zealand.
Uphononongo olulindelekileyo, lweziko elilodwa, oluvulelekileyo luvavanya ukhuseleko kunye nokusebenza kakuhle kwe-Eye90 microspheres kwizigulane ezine-hepatocellular carcinoma (HCC) engabonakaliyo okanye i-metastatic colorectal cancer (mCRC). Izigulane ziya kufumana unyango olulodwa lwe-Eye90 microspheres radioembolization kunye nokutyelela ngokulandelelana unyaka omnye ukuvavanya ukhuseleko, ukusebenza kakuhle, kunye nomgangatho wemilinganiselo yobomi.
I-Eye90 microspheres zii-radiopaque glass microspheres ezibonakalayo kwi-x-reyi kunye neComputed Tomography (CT) imaging kwaye iqulethe iYttrium 90 (Y90) radiotherapeutic element. I-Y90 radioembolization, ibrachytherapy yendawo, okwangoku isetyenziselwa ukunyanga amathumba esibindi anobungozi. Umhlaza wesibindi sokuqala ngowona mhlaza ufunyaniswayo kwaye ungowesithathu unobangela wokufa komhlaza kwihlabathi liphela, malunga nama-906,000 amatyala amatsha ngonyaka. I-HCC ngowona mhlaza wesibindi uxhaphakileyo oquka i-75% -85% yazo zonke iimeko zomhlaza wesibindi eziphambili 1 kunye nesininzi sezigulane ezifunyanwe zinesifo esinganyangekiyo. Umhlaza weColorectal (CRC) ngowona mhlaza wesithathu ufunyanwe ngowona mhlaza2, malunga ne-22% ye-CRCs ekhoyo njenge-mCRC ekuxilongeni kokuqala, kwaye malunga ne-70% yezigulane ekugqibeleni ziya kuphuhlisa i-metastatic relapse.3
UMike Mangano, uMongameli kunye ne-CEO ye-ABK Biomedical, uthe, "Sivuyiswe kukuba ukusebenzisana kwethu kwekliniki kunye noDkt Andrew Holden kunye nesibhedlele sase-Auckland, i-NZ, ifikelele kule nkqubela ebalulekileyo. Sikholelwa ukuba i-Eye90 microspheres inamandla okuqhubela phambili unyango lwe-radioembolization ye-Y90 kwixesha elitsha leziphumo eziphuculweyo zezigulane. Ngokukodwa, sijonge phambili ekufundeni eyona nkqubela phambili yobugcisa ibonelelwa yi-Eye90 microspheres ngaphezulu kwezixhobo eziqhelekileyo ze-Y90 radioembolization. Ezi ziquka inkqubo yonikezelo oluphezulu oluvumela ulawulo logqirha, ukubonwa kwe-tumor-targeting, kunye nokubanakho kwedatha ye-x-ray-based imaging yesisombululo esiphezulu, i-CT-based, i-Eye90 microspheres precision dosimetry™". UGqr Robert Abraham, iGosa eliPhezulu lezoNyango kunye nomseki we-ABK Biomedical uthe, "Kuye kwaba luhambo olumangalisayo lokuthatha inkampani ukusuka kwingcamango ukuya kunyango lwesigulane. Sinomdla kwaye sinethemba ngekamva le-ABK kunye ne-Eye90 microspheres. "
U-Andrew Holden, MD, MBChB, FRANZCR, EBIR, ONZM, umphandi oyintloko wophando, wathi, "Sizukiswa ukuba sibe ngabokuqala ukuphatha izigulane ezinobuchwephesha obuphezulu kunye nokukhokela olu cwaningo lubalulekileyo lweklinikhi oluvavanya le teknoloji entsha. Kukho inani elikhulayo lezifundo ze-Y90 ze-radioembolization ezipapashiweyo ezibonisa ukusebenza kwekliniki kwizigulane ezikhethwe ngokufanelekileyo. Sinothakazelelo lokuvavanya ukuba i-Eye90 microspheres, kunye nenkqubo yokuhanjiswa kwempahla kunye neempawu zokucinga ezikumgangatho ophezulu zinokuchaphazela iziphumo zeklinikhi ze-Y90 kunyango lwezigulana ezine-HCC kunye ne-mCRC yesibindi. "
INTO ONOKUYITHATHA KWELI NQAKU:
- The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients with unresectable hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC).
- announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers.
- HCC is the most common primary liver cancer comprising 75%-85% of all primary liver cancer cases 1 with the majority of patients diagnosed .
